Sutro Biopharma (STRO) Expected to Announce Earnings on Monday

Sutro Biopharma (NASDAQ:STRO) is expected to be releasing its earnings data before the market opens on Monday, March 24th. Analysts expect Sutro Biopharma to post earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The company had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $10.44 million. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. During the same period last year, the company earned ($1.78) earnings per share. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Stock Down 3.7 %

Shares of Sutro Biopharma stock opened at $0.77 on Friday. The company has a market cap of $63.24 million, a PE ratio of -0.48 and a beta of 1.22. Sutro Biopharma has a 52 week low of $0.76 and a 52 week high of $6.13. The business has a 50 day moving average price of $1.64 and a 200-day moving average price of $2.61.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on STRO. HC Wainwright reissued a “neutral” rating and issued a $2.00 price objective (down from $12.00) on shares of Sutro Biopharma in a research note on Monday, March 17th. Piper Sandler set a $2.00 price target on Sutro Biopharma in a research report on Friday, March 14th. Bank of America downgraded Sutro Biopharma from a “buy” rating to an “underperform” rating and decreased their price target for the company from $11.00 to $1.00 in a research report on Friday, March 14th. Wells Fargo & Company decreased their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Finally, Citizens Jmp downgraded Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Sutro Biopharma presently has an average rating of “Hold” and a consensus target price of $6.63.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.